Bristol Myers Squibb Company
NEWS
Bristol-Myers will become a limited partner, investing in projects of mutual interest, with an option to buy the companies once there is a preclinical candidate.
BMS and Celgene first announced the probable sale of the asset earlier this summer as a means to smooth out the anti-trust review process of the merger from the Federal Trade Commission.
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!
Researchers with Johns Hopkins Kimmel Cancer Center recently published research that followed 270 cancer patients treated with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab). The research reported impressive improvements in five-year survival rates.
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
Here’s a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Co. have teamed up to study the most common type of metastatic colorectal cancer (mCRC).
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
JOBS
IN THE PRESS